<DOC>
	<DOCNO>NCT01107587</DOCNO>
	<brief_summary>The purpose study assess reactogenicity safety GSK Biologicals ' liquid human rotavirus vaccine healthy infant age 6 16 week time first dose vaccination .</brief_summary>
	<brief_title>Study Assess Safety GSK Biologicals ' Liquid Human Rotavirus Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . A male female infant Chinese origin , include , 6 16 week age time first vaccination . Written inform consent obtain parent ( ) / Legally Acceptable Representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth ( corticosteroid , mean prednisone , equivalent , &gt; = 0.5 mg/kg/day . Inhaled topical steroid allow ) . Planned administration/administration vaccine foreseen study protocol within 30 day first dose human rotavirus vaccine placebo except routine childhood vaccination . Any clinically significant history gastrointestinal disease include uncorrected congenital malformation gastrointestinal tract would predispose intussusception . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . Acute disease time enrolment.. History confirm rotavirus gastroenteritis . Gastroenteritis within 7 day precede study vaccine placebo administration . Previous vaccination rotavirus vaccine plan use study period . Administration immunoglobulins and/or blood product since birth plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Human rotavirus vaccine</keyword>
</DOC>